Clinical Trial Update: Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Taxol (paclitaxel) given intravenously and intraperitoneally with Tasigna (nilotinib) taken orally for peritoneal carcinomatos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Appendiceal Cancer
• Breast Cancer
• Cholangiocarcinoma
• Colorectal Cancer
• Gastric Cancer
• Ovarian Cancer
• Peritoneal Carcinomatosis
• Small Bowel Cancer

Drugs mentioned

• Tasigna (nilotinib)
• Taxol (paclitaxel)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Gynecologic Cancer, Gynecologic Neoplasms | Phase 2 | Status: ACTIVE_NOT_RECRUITING